COSCIENS Biopharma Inc. (CSCIF) Return on equity 2016–2025
COSCIENS Biopharma Inc. (CSCIF) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-269.6%FY2025 · since FY2016: -401.8% → -269.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -269.6% | -153.3 pp |
| FY2024 | -116.3% | -99.8 pp |
| FY2023 | -16.6% | -31.0 pp |
| FY2022 | 14.5% | +52.6 pp |
| FY2021 | -38.1% | +0.6 pp |
| FY2020 | -38.7% | — |
| FY2018 | 219.6% | — |
| FY2016 | -401.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice